Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2043105 |
| _version_ | 1797673180979003392 |
|---|---|
| author | Greg Maguire |
| author_facet | Greg Maguire |
| author_sort | Greg Maguire |
| collection | DOAJ |
| description | Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and dosing strategy to induce “physiological renormalization” to induce mimicry in the innate and adaptive immune systems in the respiratory tracts and sera, similar to that when the body encounters the natural infectious agent. |
| first_indexed | 2024-03-11T21:41:19Z |
| format | Article |
| id | doaj.art-05c32d98f0c54a0bba17f42a0aa58f56 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:19Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-05c32d98f0c54a0bba17f42a0aa58f562023-09-26T13:19:05ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20431052043105Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an exampleGreg Maguire0The California Physiological SocietyCurrent vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and dosing strategy to induce “physiological renormalization” to induce mimicry in the innate and adaptive immune systems in the respiratory tracts and sera, similar to that when the body encounters the natural infectious agent.http://dx.doi.org/10.1080/21645515.2022.2043105 |
| spellingShingle | Greg Maguire Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example Human Vaccines & Immunotherapeutics |
| title | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
| title_full | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
| title_fullStr | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
| title_full_unstemmed | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
| title_short | Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example |
| title_sort | using a systems therapeutic for physiological renormalization approach to vaccine development covid 19 as an example |
| url | http://dx.doi.org/10.1080/21645515.2022.2043105 |
| work_keys_str_mv | AT gregmaguire usingasystemstherapeuticforphysiologicalrenormalizationapproachtovaccinedevelopmentcovid19asanexample |